Liquid biopsies may be used to analyze ctDNA and provide information about a patient’s eligibility for any line of treatment with anti-EGFR mAbs and subsequent rechallenge with this therapy, as the analysis of ctDNA found in the bloodstream can reveal genetic changes occurring in the tumor (37). This evidence concerns the gene EGFR and neoplasm.